These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 788837)
21. The management of haemoglobinopathies. Davies SC; Wonke B Baillieres Clin Haematol; 1991 Apr; 4(2):361-89. PubMed ID: 1912665 [No Abstract] [Full Text] [Related]
22. [Thalassemia major: chelating therapy with deferoxamine]. Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934 [No Abstract] [Full Text] [Related]
23. Desferrioxamine-induced iron outputs in Cooley's anemia. Results and perspectives. Cantore N; Tortarolo M; Volpe E; Gonnella F; Valente A; Buonanno G Haematologica; 1981 Apr; 66(2):196-207. PubMed ID: 6791996 [No Abstract] [Full Text] [Related]
24. Advances in the use of iron-chelating agents for the treatment of iron overload. Modell B Prog Hematol; 1979; 11():267-312. PubMed ID: 392593 [No Abstract] [Full Text] [Related]
25. Thalassemia. Poncz M; Cohen A; Schwartz E Adv Pediatr; 1984; 31():43-86. PubMed ID: 6516946 [No Abstract] [Full Text] [Related]
27. Current therapy and new approaches to the treatment of thalassemia major. Wolfe L; Sallan D; Nathan DG Ann N Y Acad Sci; 1985; 445():248-55. PubMed ID: 3860127 [No Abstract] [Full Text] [Related]
28. Problems related to treatment of beta-thalassaemia major. Economidou J Paediatrician; 1982; 11(3-4):157-77. PubMed ID: 7043374 [TBL] [Abstract][Full Text] [Related]
29. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography. Flynn DM; Hoffbrand AV; Politis D Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017 [No Abstract] [Full Text] [Related]
30. Hypothyroidism in patients with thalassemia syndromes. Magro S; Puzzonia P; Consarino C; Galati MC; Morgione S; Porcelli D; Grimaldi S; Tancrè D; Arcuri V; De Santis V Acta Haematol; 1990; 84(2):72-6. PubMed ID: 2120889 [TBL] [Abstract][Full Text] [Related]
31. A successful pregnancy outcome in transfusion dependent thalassaemia major. Meadows K Aust N Z J Obstet Gynaecol; 1984 Feb; 24(1):43-4. PubMed ID: 6588961 [TBL] [Abstract][Full Text] [Related]
32. Clinical management of thalassemia. Decreasing iron stores during intensive chelation therapy. Cohen A; Schwartz E Ann N Y Acad Sci; 1980; 344():405-8. PubMed ID: 6930880 [No Abstract] [Full Text] [Related]
33. Modern management of thalassemia. Festa RS Pediatr Ann; 1985 Sep; 14(9):597-600, 602-3, 606. PubMed ID: 3903631 [No Abstract] [Full Text] [Related]
35. Urinary iron excretion in thalassaemia after desferrioxamine administration. Seshadri R; Colebatch JH; Fisher R Arch Dis Child; 1974 Mar; 49(3):195-9. PubMed ID: 4825624 [TBL] [Abstract][Full Text] [Related]
36. [Treatment of post-transfusion iron overload by deferoxamine]. de Montalembert M; Llados A; Hannedouche T; Girot R Arch Fr Pediatr; 1989 Feb; 46(2):99-105. PubMed ID: 2735804 [TBL] [Abstract][Full Text] [Related]
37. Peripheral neuropathy in thalassaemia. Sawaya RA; Zahed L; Taher A Ann Saudi Med; 2006; 26(5):358-63. PubMed ID: 17019100 [TBL] [Abstract][Full Text] [Related]
39. Iron metabolism and iron chelation in the thalassaemia disorders. Pippard MJ Haematologica; 1990; 75 Suppl 5():66-71. PubMed ID: 2086383 [No Abstract] [Full Text] [Related]
40. Liver iron stores before and after bone marrow transplantation for thalassemia. Politi P; Lucarelli G; Capriotti L; Salvadori P; Dardanelli C; Barbanti I Prog Clin Biol Res; 1989; 309():281-9. PubMed ID: 2675096 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]